Cumberland Pharmaceuticals (CPIX) Income from Non-Controlling Interests (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) posted Income from Non-Controlling Interests of $2588.0 for Q1 2026, up 115.27% sequentially from -$16950.0 in Q4 2025, and up 129.13% YoY from $1129.5 in Q1 2025.
Cumberland Pharmaceuticals (CPIX) Income from Non-Controlling Interests (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has reported Income from Non-Controlling Interests for 17 years, with the latest figure at $2588.0 in Q1 2026.
- Quarterly Income from Non-Controlling Interests rose 129.13% year-over-year to $2588.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17111.0 (down 2.95% YoY) and the FY2025 annual result came in at -$28583.0, down 179.28% from the prior year.
- Income from Non-Controlling Interests grew to $2588.0 in Q1 2026 per CPIX's latest filing, from -$16950.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $43791.0 in Q1 2024 and troughed at -$29046.0 in Q2 2022.
- A 5-year average of -$7128.5 and a median of -$10046.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2024 and 2025: Income from Non-Controlling Interests soared 320.08% in 2024, then slumped 878.59% in 2025.
- Over 5 years, Income from Non-Controlling Interests stood at -$18985.0 in 2022, then soared by 60.07% to -$7581.0 in 2023, then soared by 128.72% to $2177.0 in 2024, then plunged by 878.59% to -$16950.0 in 2025, then soared by 115.27% to $2588.0 in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $2588.0, -$16950.0, and -$8282.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Cumberland Pharmaceuticals | 116.48 Mn | 112.62 Mn | - | 1,947.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,947.00 |
| Mar 31, 2026 | 2,588.00 |
| Dec 31, 2025 | -16,950.00 |
| Sep 30, 2025 | -8,282.00 |
| Jun 30, 2025 | 5,533.00 |
| Mar 31, 2025 | -8,884.00 |
| Dec 31, 2024 | 2,177.00 |
| Sep 30, 2024 | 7,112.00 |
| Jun 30, 2024 | -17,025.00 |
| Mar 31, 2024 | 43,791.00 |
| Dec 31, 2023 | -7,581.00 |
| Sep 30, 2023 | -13,921.00 |
| Jun 30, 2023 | -10,046.00 |
| Mar 31, 2023 | -19,898.00 |
| Dec 31, 2022 | -18,985.00 |
| Sep 30, 2022 | -14,587.00 |
| Jun 30, 2022 | -29,046.00 |
| Mar 31, 2022 | -17,180.00 |
| Dec 31, 2021 | -36,561.00 |
| Sep 30, 2021 | -31,415.00 |